Drs Jacob Sands and Jia Luo discuss NUT carcinoma, including diagnostic challenges, emerging treatments, clinical trial options, and the NUT carcinoma registry.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999032. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics https://pubmed.ncbi.nlm.nih.gov/35372003/

The MYC Oncogene — The Grand Orchestrator of Cancer Growth and Immune Evasion https://pubmed.ncbi.nlm.nih.gov/34508258/

SOX2 Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype https://pubmed.ncbi.nlm.nih.gov/34593608/

Next-Generation Sequencing in Cancer https://pubmed.ncbi.nlm.nih.gov/34408360/

PET Scanning https://www.ncbi.nlm.nih.gov/books/NBK559089/

Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma https://pubmed.ncbi.nlm.nih.gov/38154515/

International NUT Carcinoma Registry https://nc-registry.org/

Automated Tumor Proportion Score Analysis for PD-L1 (22C3) Expression in Lung Squamous Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/34354151/

Ewing Sarcoma https://emedicine.medscape.com/article/990378-overview?form=fpf

Improving Lung Cancer Patient Care Through Collaboration, Psychology, and Communication https://www.medscape.com/viewarticle/999028

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications https://pubmed.ncbi.nlm.nih.gov/37049806/

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma https://clinicaltrials.gov/study/NCT05019716

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors https://clinicaltrials.gov/study/NCT05372640

Development of CDK4/6 Inhibitors: A Five Years Update https://pubmed.ncbi.nlm.nih.gov/33803309/

A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma https://www.clinicaltrials.gov/search?cond=NCT04718675

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors https://clinicaltrials.gov/study/NCT05488548

Drs Jacob Sands and Hossein Borghaei discuss small cell lung cancer, including breakthroughs and challenges in immunotherapy.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999031. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/30280641/

Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/31590988/

Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17167137/

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort https://pubmed.ncbi.nlm.nih.gov/31629915/

Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/25891174/

Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer (KEYNOTE-001): 3-Year Results From an Open-Label, Phase 1 Study https://pubmed.ncbi.nlm.nih.gov/30876831/

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/10080612/

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17135646/

Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://pubmed.ncbi.nlm.nih.gov/32224306/

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group https://pubmed.ncbi.nlm.nih.gov/21115872/

Beyond Overall Survival: Considering Quality of Life in the Treatment of Early Non-Small Cell Lung Cancer https://www.medscape.com/viewarticle/999479

Tarlatamab for Patients With Previously Treated Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/37861218/

Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999030. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress https://pubmed.ncbi.nlm.nih.gov/37163707/

TROP-2 Directed Antibody-Drug Conjugates (ADCs): The Revolution of Smart Drug Delivery in Advanced Non-Small Cell Lung Cancer (NSCLC) https://pubmed.ncbi.nlm.nih.gov/37230055/

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan https://pubmed.ncbi.nlm.nih.gov/28548889/

Gilead Provides Update on Phase 3 EVOKE-01 Study https://www.gilead.com/news-and-press/press-room/press-releases/2024/1/gilead-provides-update-on-phase-3-evoke-01-study

EVOKE-02: A Phase 2 Study of Sacituzumab Govitecan (SG) Plus Pembrolizumab (Pembro) With or Without Platinum Chemotherapy in First-Line Metastatic Non–Small Cell Lung Cancer (NSCLC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS9146

Datopotamab Deruxtecan Met the PFS Endpoint in Previously Treated NSCLC https://dailyreporter.esmo.org/esmo-congress-2023/non-small-cell-lung-cancer/datopotamab-deruxtecan-met-the-pfs-endpoint-in-previously-treated-nsclc

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells https://pubmed.ncbi.nlm.nih.gov/34413126/

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial https://pubmed.ncbi.nlm.nih.gov/37694347/

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/36288547/

Press Release: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint https://www.globenewswire.com/news-release/2023/12/21/2799759/0/en/Press-Release-Sanofi-announces-end-of-program-evaluating-tusamitamab-ravtansine-after-a-2L-NSCLC-Phase-3-trial-did-not-meet-a-primary-endpoint.html

Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm? https://pubmed.ncbi.nlm.nih.gov/37370772/

BL-B01D1, a First-in-Class EGFRxHER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients With Locally Advanced or Metastatic Solid Tumor: Results From a First-in-Human Phase 1 Study https://meetings.asco.org/abstracts-presentations/218492

Drs Jacob Sands and Narjust Florez discuss the nuances of treating women with lung cancer, including screening, treatment, and sexual and reproductive health.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999029). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

The Role of Cultural Humility in Addressing Disparities in Lung Cancer Treatment: How Can Physicians Make a Difference? https://www.medscape.com/viewarticle/969537

Higher Lung Cancer Incidence in Young Women Than Young Men in the United States https://pubmed.ncbi.nlm.nih.gov/29791813/

Sexual Health Assessment in Women With Lung Cancer Study: Sexual Health Assessment in Women With Lung Cancer https://pubmed.ncbi.nlm.nih.gov/37843054/

EGFR Resisters https://egfrcancer.org/

GO2 for Lung Cancer https://go2.org/

Drs Jacob Sands and Donald L. Rosenstein discuss the psychology of lung cancer and how to effectively communicate with patients about diagnosis, treatment, and expectations.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999028). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2

The Flourishing Scholarship of Psychosocial Oncology Viewed Across 30 Years Through the Lens of This Journal, Psycho-Oncology https://pubmed.ncbi.nlm.nih.gov/35396891/

Living With and Beyond Cancer: Psychosocial and Psychological Support for Patients From Diagnosis Through Survivorship https://www.medscape.com/viewarticle/985096

"Scanxiety" and a Sense of Control: The Perspective of Lung Cancer Survivors and Their Caregivers on Follow-up - A Qualitative Study https://pubmed.ncbi.nlm.nih.gov/37069692/

Psychotherapy Alone Versus Collaborative Psychotherapy and Psychiatric Care in the Treatment of Depression and Anxiety in Patients With Cancer: A Naturalistic, Observational Study https://pubmed.ncbi.nlm.nih.gov/37209423/

Creating a Proactive Interdisciplinary Approach to Care: Embedding Oncology Care Coordination Within an Oncology Patient and Family Support Program https://ascopubs.org/doi/10.1200/JCO.2022.40.28_suppl.051

Use of PHQ-9 for Monitoring Patients With Depression in Integrated Primary Care Practices https://pubmed.ncbi.nlm.nih.gov/36693193/

Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a Primary Care Setting https://pubmed.ncbi.nlm.nih.gov/32582485/

Implementing Collaborative Care for Major Depression in a Cancer Center: An Observational Study Using Mixed-Methods https://pubmed.ncbi.nlm.nih.gov/35305403/

Drs Jacob Sands and Julia Rotow discuss the latest breakthroughs in lung cancer treatment, including targeted therapy options, toxicities, and diagnostic technology.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999027). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening https://www.medscape.com/viewarticle/984258

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34127383/

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/29151359/

Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2). 2023 World Conference on Lung Cancer. Abstract PL03.13. https://www.sciencedirect.com/science/article/abs/pii/S1556086423008110

MARIPOSA: Phase 3 Study of First-Line Amivantamab + Lazertinib Versus Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34911336/

Discovery of Amivantamab (JNJ-61186372), a Bispecific Antibody Targeting EGFR and MET https://pubmed.ncbi.nlm.nih.gov/33839159/

Amivantamab Plus Chemotherapy With and Without Lazertinib in EGFR-Mutant Advanced NSCLC After Disease Progression on Osimertinib: Primary Results From the Phase III MARIPOSA-2 Study https://pubmed.ncbi.nlm.nih.gov/37879444/

Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/33380864/

Next Generation Sequencing Technology in Lung Cancer Diagnosis https://pubmed.ncbi.nlm.nih.gov/34571741/

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress https://pubmed.ncbi.nlm.nih.gov/33558193/

[NCT03456076] A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03456076

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies https://pubmed.ncbi.nlm.nih.gov/33172113/

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2302299

NCCN Guidelines: Non-Small Cell Lung Cancer https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450

Amivantamab Plus Chemotherapy in NSCLC With EGFR Exon 20 Insertions https://pubmed.ncbi.nlm.nih.gov/37870976/

Drs Jacob Sands and Christopher Lathan, MD, discuss stigma, clinician bias, financial toxicity, and treatment disparities in lung cancer, including helpful practices such as "following the no."

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984264). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2

Racial and Ethnic Disparities https://www.lung.org/research/state-of-lung-cancer/racial-and-ethnic-disparities

Stage IIIB Non–Small Cell Lung Cancer https://www.cancer.gov/publications/dictionaries/cancer-terms/def/stage-iiib-non-small-cell-lung-cancer

Curative, Life-Extending, and Palliative Chemotherapy: New Outcomes Need New Names https://pubmed.ncbi.nlm.nih.gov/28550031/

Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/26926678/

How Structural Racism Works – Racist Policies as a Root Cause of US Racial Health Inequities https://pubmed.ncbi.nlm.nih.gov/33326717/

Drs Jacob Sands and Stephen V. Liu discuss immunotherapy, biomarkers, next-generation sequencing, shared decision-making, and improving outcomes in the treatment of non–small cell lung cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984262). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/30955977/

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer Without Tumor PD-L1 Expression: A Pooled Analysis of 3 Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/32914866/

Patient-Reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients With Previously Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/32035514/

Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/30280635/

Nanoparticle Albumin-Bound Paclitaxel: A Novel Cremphor-EL®-Free Formulation of Paclitaxel https://www.medscape.com/viewarticle/563323_4

Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/29658856/

First-line Treatment With Ipilimumab Plus Nivolumab for NSCLC https://decisionpoint.medscape.com/oncology/viewarticle/925934

Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/31562796/

First-line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33476593/

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study https://pubmed.ncbi.nlm.nih.gov/36327426/

The importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912095/

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/29773717/

Atezolizumab for First-line Treatment of PD-L1-Selected Patients With NSCLC https://pubmed.ncbi.nlm.nih.gov/32997907/

Atezolizumab in Combination With Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared With Chemotherapy Alone as First-line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/31122901/

Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17167137/

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor (TKI)-Resistant Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) https://clinicaltrials.gov/ct2/show/NCT03515837

Dual Inhibition of EGFR‑VEGF: An Effective Approach to the Treatment of Advanced Non‑Small Cell Lung Cancer With EGFR Mutation (Review) https://pubmed.ncbi.nlm.nih.gov/36601768/

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34127383/

Drs Jacob Sands and Chi-Fu J. Yang discuss lung cancer screening trials and the intersection of guidelines and clinical judgment in evaluation of suspicious nodules.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984261). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Rescue Lung Society https://rescuelung.org/

Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2

American Lung Cancer Screening Initiative https://www.alcsi.org/

Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview

Lung Cancer: Screening https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening

Reduced Lung-cancer Mortality With Low-dose Computed Tomographic Screening https://pubmed.ncbi.nlm.nih.gov/21714641/

Reduced Lung-cancer Mortality With Volume CT Screening in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/31995683/

Low-dose CT Scan https://www.cancer.gov/publications/dictionaries/cancer-terms/def/low-dose-ct-scan

NELSON Study Shows CT Screening for Nodule Volume Management Reduces Lung Cancer Mortality by 26 Percent in Men https://www.iaslc.org/iaslc-news/press-release/nelson-study

Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial: New Confirmation of Lung Cancer Screening Efficacy https://pubmed.ncbi.nlm.nih.gov/30937431/

Statistical Essentials in Interpreting Clinical Trials https://www.medscape.com/viewarticle/863840

American Lung Association State of Lung Cancer https://www.lung.org/research/state-of-lung-cancer

Lung CT Screening Reporting & Data System (Lung-RADS®) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads

Surgical Outcomes in a Large, Clinical, Low-dose Computed Tomographic Lung Cancer Screening Program https://pubmed.ncbi.nlm.nih.gov/26209493/

Navigational Bronchoscopy: A Guide Through History, Current Use, and Developing Technology https://pubmed.ncbi.nlm.nih.gov/32642249/

PET Scan https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pet-scan

Lung Screening Benefits and Challenges: A Review of the Data and Outline for Implementation https://pubmed.ncbi.nlm.nih.gov/33188913/

Drs Jacob Sands and Jamie Chaft discuss the past, present, and future of perioperative management of lung cancer, including data from recent trials, disease-free survival outcomes, and changes in the standard of care.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984259). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/14736927/

Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non–Small-Cell Lung Cancer (IMpower010): A Randomized, Multicentre, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/34555333/

Integration of Immunotherapy Into Adjuvant Therapy for Resected Non–Small-Cell Lung Cancer: ALCHEMIST Chemo-IO (ACCIO) https://pubmed.ncbi.nlm.nih.gov/33878954/

Pembrolizumab Versus Placebo as Adjuvant Therapy for Completely Resected Stage IB-IIIA Non–Small-Cell Lung Cancer (PEARLS/KEYNOTE-091): An Interim Analysis of a Randomized, Triple-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/36108662/

ADAURA: Phase III, Double-Blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-Stage NSCLC After Complete Surgical Resection https://pubmed.ncbi.nlm.nih.gov/29789220/

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/

Osimertinib as Adjuvant Therapy in Patients (pts) With Stage IB–IIIA EGFR Mutation Positive (EGFRm) NSCLC After Complete Tumor Resection: ADAURA. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA5

American Joint Committee on Cancer https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/

Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/28885881/

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non–Small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) https://www.clinicaltrials.gov/ct2/show/NCT02595944

ALINA: A Phase III Study of Alectinib Versus Chemotherapy as Adjuvant Therapy in Patients With Stage IB–IIIA Anaplastic Lymphoma Kinase-Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC). https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.TPS8569

Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer https://pubmed.ncbi.nlm.nih.gov/35403841/